COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,490 Articles (22,862 medRxiv, 8,628 bioRxiv)

Most recent first Previous |  Page 1143: Articles 11421-11430  | Next

Failure of Concentric Regulatory Zones to Halt the Spread of COVID-19 in South Brooklyn, New York: October-November 2020
Harris, J.
10.1101/2021.11.18.21266493 — Posted: 2021-11-21
Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodies
Klegerman, M. E., Peng, T., Seferovich, I., Rahbar, M. H., Hessabi, M., Tahanan, A., Wanger, A., Grimes, C. Z., Ostrosky-Zeichner, L. Z., Koster, K., Cirillo, J. D., Abeydeera, D., De Lira, S., McPherson, D. D.
10.1101/2021.11.19.21266547 — Posted: 2021-11-21
Effectiveness of Vaccination Against Reported SARS-CoV-2 Infection in United States Coast Guard Personnel Between May and August 2021: A Time-Series Analysis
Iskander, J., Frost, J. K., Russell, S., Ahluwalia, J., Ward, E., Steiner, S., Thomas, D., Michaud, P.
10.1101/2021.11.19.21266537 — Posted: 2021-11-21
Risk factors for workplace bullying, severe psychological distress, and suicidal ideation during the COVID-19 pandemic: a nationwide internet survey for the general working population in Japan
Tsuno, K., Tabuchi, T.
10.1101/2021.11.18.21266501 — Posted: 2021-11-21
An integrative method for COVID-19 patients classification from chest X-ray using deep learning network with image visibility graph as feature extractor
Pal, M., Tiwari, Y., Reddy, T. V., Parisineni, S. R. A., Panigrahi, P. K.
10.1101/2021.11.17.21266472 — Posted: 2021-11-21
COVID-19 testing systems and their effectiveness in small, semi-isolated groups for sports events
Kamo, M., Murakamo, M., Naito, W., Takeshita, J.-i., Yasutaka, T., Imoto, S.
10.1101/2021.11.18.21266507 — Posted: 2021-11-21
Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course
Pillay, J., Bialy, L., Gaudet, L., Wingert, A., Mackie, A., Paterson, D. I., Hartling, L.
10.1101/2021.11.19.21266605 — Posted: 2021-11-21
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Wanlapakorn, N., Yorsaeng, R., Phowatthanasathian, H., Suntronwong, N., Kanokudom, S., Sudhinaraset, N., Poovorawan, Y.
10.1101/2021.11.20.21266644 — Posted: 2021-11-21
Comprehensive genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections: a prospective, comparative cohort study
Tian, D., Song, Y., Zhang, M., Pan, Y., Ge, Z., Zhang, Y., Ren, X., Wen, J., Xu, Y., Guo, H., Yang, P., Chen, Z., Xu, W.
10.1101/2021.11.17.21266499 — Posted: 2021-11-21
Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)
Sidler, D., Born, A., Schietzel, S., Horn, M. P., Aeberli, D., Amsler, J., Moeller, B., Njue, L. M., Medri, C., Angelillo-Scherrer, A., Borradori, L., Seyed Jafari, S. M., Radonjic-Hoesli, S., Chan, A., Hoepner, R., Bacher, U., Mani, L.-Y., Iype, J. M., Suter-Riniker, F., Staehelin, C., Nagler, M., Hirzel, C., Maurer, B., Moor, M. B.
10.1101/2021.11.19.21266572 — Posted: 2021-11-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).